✦ LIBER ✦

43 Prognostic value of performance status (PS) in advanced non-small cell lung cancer (NSCLC) patients receiving gemcitabine and cisplatin

✍ Scribed by Gaafar, R.; Sallam, Y.; Khaled, H.; Mansour, O.; Abdel-Karim, N.; El-Attar, I.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gene polymorphisms, pharmacokinetics, an

✍ M. Joerger; J. A. Burgers; P. Baas; V. D. Doodeman; P. H. M. Smits; R. S. Jansen 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 352 KB

PP43. Quality of life assessments of pat

✍ A Anton; A Carrato; JL Gonzalez-Larriba; C Vadel; B Masutti; J Montalar; E Arand 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 158 KB

Decreased myelotoxicity of gemcitabine a

✍ Cortesi, E.; Ramponi, S.; Corona, M.; Moscetti, L.; Grifalchi, F.; Oliva, A.; Le 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Phase II trial assessing the combination

✍ Antón, A; Dı́az-Fernández, N; González Larriba, J.L; Vadell, C; Masutti, B; Mont 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 91 KB

Pharmacology of the paclitaxel–cisplatin

✍ J. R. Kroep; E. F. Smit; G. Giaccone; K. Van der Born; J. H. Beijnen; C. J. Van 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 248 KB

159 Phase II trial of gemcitabine in com

✍ Mohedano, N.; Sanchez-Rovira, P.; Medina, B.; Flores-Gonzalez, E.; Moreno, M.A.; 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 158 KB